TALAPRO-2: Talazoparib/enzalutamide confers significant OS benefit in mCRPC
The investigators reported an HR for OS of 0.796 (95% CI, 0.661-0.958; 2-sided P = .0155) for talazoparib/enzalutamide vs enzalutamide/placebo.
Related Articles
Step Counts: A Simple Step Toward Better Health
Is it possible to utilize step counts in preventive care. That’s the question behind the recent study, “Step Count: The Next Vital Sign,” published on…
How many steps do you need in a day to be healthy? The official number just changed
Recent findings from the Texas Heart Institute suggest that health benefits begin at around 2,500 steps per day, with optimal benefits observed between 7,000 and…
Aircraft carrier Harry S. Truman collides with ship in Mediterranean Sea
The aircraft carrier USS Harry S. Truman collided with a large merchant vessel Wednesday night in the vicinity of Port Said, Egypt, in the Mediterranean…
US Navy’s carrier Truman involved in collision with merchant vessel, no flooding or injuries – Breaking Defense
The collision with Besiktas-M, a bulk carrier, took place in the vicinity of an Egyptian port.
Under Prescription and Medication Non-Adherence in Female Patients With Ischemic Stroke: A Call for Actions to Mitigate the Prescription Disparity Between Sexes
Ho Man (Steven) Lam, PhD, MPH Secondary stroke prevention is a fundamental principle in the clinical management of patients with stroke or transient ischemic attack.…
CVRx Barostim Demonstrates Reduction in Health Care Use in Real-World Data – Endovascular Today
February 12, 2025—CVRx, Inc. announced new real-world evidence demonstrating that use of the company’s Barostim implant was associated wit
Women
Learn how women living with heart disease and stroke are impacted by gaps in research, diagnosis and care.
Mitigating Post-Operative Right Ventricular Dysfunction After Left Ventricular Assist Device: The RV Protection Study
Left ventricular assist devices (LVADs) are an important medical advancement for patients with advanced heart failure, with higher survival rates compared to medical therapy alone.1…
Association of Circulating Phenylacetylglutamine With Multi‐Vessel Coronary Disease Severity and Outcomes in ST‐Segment–Elevation Myocardial Infarction | Journal of the American Heart Association
BackgroundThere is a lack of evidence regarding the association between plasma phenylacetylglutamine levels and lesion severity and clinical prognosis in patients with ST‐segment elevation myocardi…
